



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 19-384/S-053

Merck & Co., Inc.  
Attention: Mr. Peter Kusma  
Manager, Regulatory Affairs  
P.O. Box 1000, UG2CD-48  
North Wales, PA 19454-1099

Dear Mr. Kusma:

Please refer to your supplemental new drug application (NDA) dated and received October 9, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for NOROXIN<sup>®</sup> (norfloxacin) Tablets.

We acknowledge receipt of your submission dated January 14, 2009.

This supplemental new drug application provides for the following changes to the carton and container labels:

- Addition of the statement: "Attention Pharmacist: Dispense the accompanying Medication Guide to each patient."

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (immediate container and carton labels).

As soon as possible, but no later than 14 days from the date of this letter, please submit the final printed immediate container and carton labels. For administrative purposes, please designate this submission, "**Carton and Container Labels for approved supplement NDA 19-384/S-053.**"

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
Suite 12B05  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Hyun Son, Pharm.D., Acting Safety Regulatory Project Manager, at (301) 796-1600.

Sincerely,

*{See appended electronic signature page}*

Ozlem Belen, M.D., MPH  
Deputy Director for Safety  
Division of Special Pathogen and Transplant  
Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Ozlem Belen  
2/12/2009 01:24:52 PM